1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > North American Nuclear Medicine/Radiopharmaceuticals Market by Type, Therapeutic, by Application - Forecasts to 2020

The North American nuclear medicine/radiopharmaceuticals market is poised to reach USD 2.98 billion by 2020 from USD 1.97 billion in 2015, growing at a CAGR of 8.6% during the forecast period of 2015 to 2020.

Nuclear medicine is a specialized field of medicine that covers all aspects of the use of radioactive substances, through either injection or ingestion, for the diagnosis or treatment of diseases such as cancer, cardiovascular disease, and neurological diseases. The nuclear medicine/radiopharmaceuticals market is bifurcated into diagnostic and therapeutic segments. Radiopharmaceuticals in the diagnostics market are categorized as SPECT and PET, whereas radiopharmaceuticals in the therapeutics market are categorized as beta emitters, brachytherapy isotopes, and alpha emitters.

In 2015, the diagnostic segment accounted for the largest share of the North American nuclear medicine/radiopharmaceuticals market, by type. Moreover, the SPECT segment is expected to account for the largest share of the North American diagnostic nuclear medicine/radiopharmaceuticals market. This can be attributed to growing cancer patient population, increasing preference for SPECT procedures, advances in SPECT radioisotopes, and cyclotron-based Tc-99m generation. In addition, in 2015, the beta emitters segment is expected to account for the largest share of the North American therapeutic nuclear medicine/radiopharmaceuticals market, owing to heavy funding for research on beta emitters, new therapeutic radioisotopes, and reimbursement policies in favor of using radiopharmaceuticals for cancer therapy.

In 2015, the cardiology application accounts for the largest share of North American nuclear medicine/radiopharmaceuticals market for SPECT applications. This large share can be attributed to new hardware and software designs in SPECT, rising incidence rate of CVDs, and adoption of SPECT in new cardiac applications. The PET market is dominated by oncology applications owing to its accuracy, and preference of PET over conventional imaging. In 2015, the therapeutic market is dominated by thyroid applications. This large share of thyroid applications can be attributed to the factors such as non-invasive method for treatment, and growing incidence of thyroid cancer.

In 2015, U.S. is expected to account for the largest share of the North American nuclear medicine/radiopharmaceuticals market, followed by Canada. The U.S. market is also likely to witness the highest growth rate of the North American nuclear medicine/radiopharmaceuticals market in the coming years. The U.S.’s large share and high growth rate can be attributed to the focus on domestic production of Mo-99, the approval of new radiopharmaceuticals by the FDA in the U.S., FDA approval for alpha emitter, growing focus on therapeutic nuclear medicine as an alternative treatment in oncology, and growing incidence of thyroid cancer.

The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies (agreements, collaborations, contracts, and partnerships, marketing and promotions, new product launches, expansions, acquisitions, funding and grants, patent coverage extensions, website launches, and license renewals) to increase their market shares and establish a strong foothold in the North American market.

Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps the firms to garner a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios of top players in the North American nuclear medicine/radiopharmaceuticals market. The report analyzes the North American nuclear medicine/radiopharmaceuticals, by type of isotopes, applications, and country
- Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the North American nuclear medicine/radiopharmaceuticals market
- Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various nuclear medicine products, applications, and technologies across countries
- Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the North American nuclear medicine/radiopharmaceuticals market
- Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the North American nuclear medicine/radiopharmaceuticals market

Table Of Contents

North American Nuclear Medicine/Radiopharmaceuticals Market by Type, Therapeutic, by Application - Forecasts to 2020
TABLE OF CONTENTS

1 INTRODUCTION 19
1.1 OBJECTIVES OF STUDY 19
1.2 MARKET DEFINITION 19
1.3 MARKET SCOPE 19
1.3.1 MARKETS COVERED 20
1.3.2 YEARS CONSIDERED FOR THE STUDY 21
1.4 CURRENCY 21
1.5 LIMITATIONS 21
1.6 STAKEHOLDERS 21
2 RESEARCH METHODOLOGY 22
2.1 RESEARCH METHODOLOGY STEPS 22
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 23
2.2.1 SECONDARY RESEARCH 23
2.2.2 PRIMARY RESEARCH 24
2.2.2.1 Key industry insights 25
2.2.2.2 Key data from primary sources 26
2.2.2.3 Key Insights from primary sources 26
2.3 MARKET SIZE ESTIMATION METHODOLOGY 27
2.4 RESEARCH DESIGN 29
2.5 MARKET DATA VALIDATION AND TRIANGULATION 30
2.6 ASSUMPTIONS FOR THE STUDY 30
3 EXECUTIVE SUMMARY 31
3.1 INTRODUCTION 31
3.2 CURRENT SCENARIO 32
3.3 FUTURE OUTLOOK 32
4 PREMIUM INSIGHTS 35
4.1 NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET 35
4.2 NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS DIAGNOSTIC MARKET, BY THERAPEUTIC AND SPECT APPLICATION 36
4.3 NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY COUNTRY 37
4.4 NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY TYPE (2015 VS. 2020) 38

5 MARKET OVERVIEW 39
5.1 INTRODUCTION 40
5.2 MARKET SEGMENTATION 40
5.3 MARKET DYNAMICS 41
5.3.1 DRIVERS 41
5.3.1.1 Increasing preference for SPECT and PET scans 41
5.3.1.2 Alpha radioimmunotherapy-based targeted cancer treatment 42
5.3.1.3 Advances in radiotracers 42
5.3.1.4 Growing incidence of cancer and CVDs 43
5.3.1.5 Rising awareness about the effective use of radiopharmaceuticals in various applications 43
5.3.2 RESTRAINTS 44
5.3.2.1 Requirement of high capital investments to limit the procurement of scanners 44
5.3.2.2 Shorter half-life of radiopharmaceuticals 44
5.3.2.3 Stringent regulatory guidelines and Good Manufacturing Practices 45
5.3.2.4 Competition from conventional diagnostic procedures 45
5.3.3 OPPORTUNITIES 46
5.3.3.1 Upcoming radioisotopes 46
5.3.3.2 Alternative diagnostic radiopharmaceutical solutions 46
5.3.3.3 Cyclotron-based production 46
5.3.3.4 Use of radiopharmaceuticals in neurological applications 47
5.3.4 CHALLENGES 48
5.3.4.1 Shutdown of nuclear reactors to impact production of radioisotopes 48
6 NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET: PIPELINE ASSESSMENT 49
6.1 INTRODUCTION 50
6.2 DIAGNOSTIC RADIOISOTOPES 53
6.3 THERAPEUTIC RADIOISOTOPES 57
7 NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY TYPE 61
7.1 INTRODUCTION 62
7.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS 64
7.2.1 SPECT RADIOPHARMACEUTICALS 65
7.2.1.1 Technetium-99m 67
7.2.1.2 Thallium-201 68
7.2.1.3 Gallium-67 69
7.2.1.4 Iodine-123 70
7.2.1.5 Other SPECT Isotopes 71

7.2.2 PET RADIOPHARMACEUTICALS 72
7.2.2.1 Fluorine-18 73
7.2.2.2 Rubidium-82 74
7.2.2.3 Other PET Isotopes 75
7.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS 76
7.3.1 BETA EMITTERS 77
7.3.1.1 Iodine-131 79
7.3.1.2 Yttrium-90 79
7.3.1.3 Samarium-153 80
7.3.1.4 Rhenium-186 81
7.3.1.5 Lutetium-177 81
7.3.1.6 Other Beta Emitter Isotopes 82
7.3.2 ALPHA EMITTERS 83
7.3.2.1 Radium-223 84
7.3.3 BRACHYTHERAPY 84
7.3.3.1 Iodine-125 86
7.3.3.2 Iridium-192 86
7.3.3.3 Palladium-103 87
7.3.3.4 Cesium-131 87
7.3.3.5 Other Brachytherapy Isotopes 88
8 NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY APPLICATION 89
8.1 INTRODUCTION 90
8.2 DIAGNOSTIC APPLICATIONS 90
8.2.1 SPECT APPLICATIONS 91
8.2.1.1 Cardiology 94
8.2.1.2 Lymphoma 95
8.2.1.3 Neurology 96
8.2.1.4 Thyroid 97
8.2.1.5 Other SPECT Applications 98
8.2.2 PET APPLICATIONS 99
8.2.2.1 Oncology 102
8.2.2.2 Cardiology 103
8.2.2.3 Neurology 103
8.2.2.4 Other PET Applications 104
8.3 THERAPEUTIC APPLICATIONS 105
8.3.1 THYROID 108
8.3.2 BONE METASTASIS 109
8.3.3 LYMPHOMA 110
8.3.4 ENDOCRINE TUMORS 110
8.3.5 OTHER THERAPEUTIC APPLICATIONS 111
9 NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME 112
9.1 INTRODUCTION 113
9.2 DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME 114
9.2.1 SPECT RADIOPHARMACEUTICALS 114
9.2.2 PET RADIOPHARMACEUTICALS 115
9.3 THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME 116
9.3.1 BETA EMITTERS 116
9.3.2 BRACHYTHERAPY 117
10 NORTH AMERICAN NUCLEAR MEDICINE/ RADIOPHARMACEUTICALS MARKET, BY COUNTRY 118
10.1 INTRODUCTION 119
10.2 DIAGNOSTIC MARKET 120
10.2.1 NORTH AMERICA 121
10.2.1.1 U.S. 122
10.2.1.1.1 DOMESTIC PRODUCTION OF MO-99 IN THE U.S. 122
10.2.1.1.2 APPROVAL OF NEW RADIOPHARMACEUTICALS BY FDA 122
10.2.1.2 CANADA 125
10.2.1.2.1 EXTENSION OF OPERATIONS AT THE CANADIAN NATIONAL RESEARCH UNIVERSAL (NRU) REACTOR 125
10.2.1.2.2 ALTERNATIVE MEDICAL ISOTOPE TECHNOLOGIES IN CANADA 125
10.3 THERAPEUTIC MARKET 128
10.3.1 NORTH AMERICA 129
10.3.1.1 U.S. 130
10.3.1.1.1 FDA APPROVAL FOR ALPHA EMITTER 130
10.3.1.1.2 THERAPEUTIC NUCLEAR MEDICINE - ALTERNATIVE TREATMENT CHOICE IN ONCOLOGY 130
10.3.1.1.3 GROWING INCIDENCE OF THYROID CANCER 130
10.3.1.2 CANADA 133
10.3.1.2.1 EXPERTISE IN ISOTOPE PRODUCTION 133
10.3.1.2.2 GOVERNMENT INITIATIVES TO INCREASE THE NUMBER OF NUCLEAR MEDICINE TREATMENT CENTERS 133
10.3.1.2.3 HIGH INCIDENCE OF CANCER 133

11 COMPETITIVE LANDSCAPE 136
11.1 OVERVIEW 136
11.2 COMPETITIVE SITUATION AND TRENDS 136
11.2.1 INTRODUCTION 137
11.2.2 AGREEMENTS, COLLABORATIONS, CONTRACTS, AND PARTNERSHIPS 138
11.2.3 MARKETING AND PROMOTIONS 139
11.2.4 NEW PRODUCT LAUNCHES 140
11.2.5 EXPANSIONS 141
11.2.6 ACQUISITIONS 142
11.2.7 OTHER STRATEGIES 143
11.3 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: EMPIRICAL ASSESSMENT OF GROWTH STRATEGIES 144
11.3.1 ROUTE TO STRATEGIC GROWTH: ORGANIC AND INORGANIC GROWTH STRATEGIES 144
11.3.2 ORGANIC GROWTH STRATEGIES 145
11.3.3 INORGANIC GROWTH STRATEGIES 146
12 COMPANY PROFILES 147
(Overview, Financials, Products and Services, Strategy, and Developments)*
12.1 INTRODUCTION 147
12.2 CARDINAL HEALTH, INC. 148
12.3 MALLINCKRODT PLC 150
12.4 GE HEALTHCARE 153
12.5 LANTHEUS MEDICAL IMAGING, INC. 155
12.6 BAYER HEALTHCARE 157
12.7 BRACCO IMAGING S.P.A 159
12.8 ECZACIBASI-MONROL NUCLEAR PRODUCTS 161
12.9 NORDION, INC. 163
12.10 ADVANCED ACCELERATOR APPLICATIONS S.A. 165
12.11 IBA MOLECULAR IMAGING 167
*Details on Financials, Product and Services, Strategy, and Developments might not be captured in case of unlisted companies.
13 APPENDIX 169
13.1 DISCUSSION GUIDE 169
13.2 AVAILABLE CUSTOMIZATIONS 176
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 177
13.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 179
13.5 RELATED REPORTS 180


LIST OF TABLES

TABLE 1 ALPHA RADIOIMMUNOTHERAPY-BASED TARGETED CANCER TREATMENT DRIVING MARKET GROWTH 44
TABLE 2 REQUIREMENT OF HIGH CAPITAL INVESTMENTS AND SHORT HALF-LIFE OF RADIOPHARMACEUTICALS RESTRAINING MARKET GROWTH 46
TABLE 3 POTENTIAL RADIOISOTOPES IN THE PIPELINE TO OFFER SIGNIFICANT GROWTH OPPORTUNITIES TO MARKET PLAYERS 47
TABLE 4 SHUTDOWN OF NUCLEAR REACTORS IS A MAJOR CHALLENGE IN THIS MARKET 48
TABLE 5 DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING DIAGNOSTIC APPLICATIONS 56
TABLE 6 DETAILS OF RADIOPHARMACEUTICALS FOR UPCOMING THERAPEUTIC APPLICATIONS 60
TABLE 7 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 63
TABLE 8 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 64
TABLE 9 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 64
TABLE 10 NORTH AMERICA: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 66
TABLE 11 NORTH AMERICA: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE, 2013-2020 (USD MILLION) 66
TABLE 12 NORTH AMERICA: TECHNETIUM-99M NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 67
TABLE 13 NORTH AMERICA: THALLIUM-201 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 68
TABLE 14 NORTH AMERICA: GALLIUM-67 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 69
TABLE 15 NORTH AMERICA: IODINE-123 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 70
TABLE 16 NORTH AMERICA: OTHER SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 71
TABLE 17 NORTH AMERICA: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 72
TABLE 18 NORTH AMERICA: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE, 2013-2020 (USD MILLION) 72
TABLE 19 NORTH AMERICA: FLUORINE-18 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 73
TABLE 20 NORTH AMERICA: RUBIDIUM-82 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 74
TABLE 21 NORTH AMERICA: OTHER PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 75
TABLE 22 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 76
TABLE 23 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 76
TABLE 24 NORTH AMERICA: BETA EMITTER NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 77
TABLE 25 NORTH AMERICA: BETA EMITTER NUCLEAR MEDICINE MARKET SIZE, BY ISOTOPE, 2013-2020 (USD MILLION) 78
TABLE 26 NORTH AMERICA: IODINE-131 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 79
TABLE 27 NORTH AMERICA: YTTRIUM-90 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 79
TABLE 28 NORTH AMERICA: SAMARIUM-153 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 80
TABLE 29 NORTH AMERICAN RHENIUM-186 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 81
TABLE 30 NORTH AMERICA: LUTETIUM-177 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 81
TABLE 31 NORTH AMERICA: OTHER BETA EMITTER NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 82
TABLE 32 NORTH AMERICA: ALPHA EMITTER NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 83
TABLE 33 NORTH AMERICA: BRACHYTHERAPY NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 85
TABLE 34 NORTH AMERICA: BRACHYTHERAPY NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY ISOTOPE, 2013-2020 (USD MILLION) 85
TABLE 35 NORTH AMERICA: IODINE-125 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 86
TABLE 36 NORTH AMERICA: IRIDIUM-192 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 86
TABLE 37 NORTH AMERICA: PALLADIUM-103 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 87
TABLE 38 NORTH AMERICA: CESIUM-131 NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION) 87
TABLE 39 NORTH AMERICA: OTHER BRACHYTHERAPY NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION) 88
TABLE 40 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS APPLICATIONS MARKET SIZE FOR SPECT ISOTOPES, BY COUNTRY,
2013-2020 (USD MILLION) 92
TABLE 41 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS APPLICATIONS MARKET SIZE FOR SPECT ISOTOPES, BY TYPE,
2013-2020 (USD MILLION) 93
TABLE 42 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY SPECT APPLICATIONS, BY COUNTRY,
2013-2020 (USD MILLION) 95
TABLE 43 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA SPECT APPLICATIONS, BY COUNTRY,
2013-2020 (USD MILLION) 96
TABLE 44 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY SPECT APPLICATIONS, BY COUNTRY,
2013-2020 (USD MILLION) 97
TABLE 45 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID SPECT APPLICATIONS, BY COUNTRY,
2013-2020 (USD MILLION) 98
TABLE 46 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER SPECT APPLICATIONS, BY COUNTRY,
2013-2020 (USD MILLION) 98
TABLE 47 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 100
TABLE 48 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR PET APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION) 101
TABLE 49 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ONCOLOGY PET APPLICATIONS, BY COUNTRY,
2013-2020 (USD MILLION) 102
TABLE 50 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR CARDIOLOGY PET APPLICATIONS, BY COUNTRY,
2013-2020 (USD MILLION) 103
TABLE 51 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR NEUROLOGY PET APPLICATIONS, BY COUNTRY,
2013-2020 (USD MILLION) 104
TABLE 52 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER PET APPLICATIONS, BY COUNTRY,
2013-2020 (USD MILLION) 104
TABLE 53 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2013-2020 (USD MILLION) 106
TABLE 54 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2013-2020 (USD MILLION) 107
TABLE 55 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR THYROID APPLICATIONS, BY COUNTRY,
2013-2020 (USD MILLION) 108
TABLE 56 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR BONE METASTASIS, BY COUNTRY, 2013-2020 (USD MILLION) 109
TABLE 57 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR LYMPHOMA, BY COUNTRY, 2013-2020 (USD MILLION) 110
TABLE 58 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR ENDOCRINE APPLICATIONS, BY COUNTRY,
2013-2020 (USD MILLION) 110
TABLE 59 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY COUNTRY,
2013-2020 (USD MILLION) 111
TABLE 60 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND UNITS) 113
TABLE 61 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME, BY COUNTRY, 2013-2020 (THOUSAND UNITS) 113
TABLE 62 NORTH AMERICA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND UNITS) 114
TABLE 63 NORTH AMERICA: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND UNITS) 114
TABLE 64 NORTH AMERICA: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND UNITS) 115
TABLE 65 NORTH AMERICA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND UNITS) 116
TABLE 66 NORTH AMERICA: BETA EMITTERS NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND UNITS) 116
TABLE 67 NORTH AMERICA: BRACHYTHERAPY NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET FOR PROCEDURAL VOLUME, BY TYPE, 2013-2020 (THOUSAND UNITS) 117
TABLE 68 NORTH AMERICA: NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 119
TABLE 69 U.S.: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 122
TABLE 70 U.S.: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY TYPE, 2013-2020 (USD MILLION) 123
TABLE 71 U.S.: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY TYPE, 2013-2020 (USD MILLION) 123
TABLE 72 U.S.: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY APPLICATION, 2013-2020 (USD MILLION) 124
TABLE 73 U.S.: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY APPLICATION, 2013-2020 (USD MILLION) 124
TABLE 74 CANADA: DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 125
TABLE 75 CANADA: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY TYPE, 2013-2020 (USD MILLION) 126
TABLE 76 CANADA: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY TYPE, 2013-2020 (USD MILLION) 126
TABLE 77 CANADA: SPECT NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY APPLICATION, 2013-2020 (USD MILLION) 127
TABLE 78 CANADA: PET NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE,
BY APPLICATION, 2013-2020 (USD MILLION) 127
TABLE 79 U.S.: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 131
TABLE 80 U.S.: BETA EMITTERS NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 131
TABLE 81 U.S.: BRACHYTHERAPY NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 132
TABLE 82 U.S.: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION) 132
TABLE 83 CANADA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 134
TABLE 84 CANADA: BETA EMITTERS NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 134
TABLE 85 CANADA: BRACHYTHERAPY NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY TYPE, 2013-2020 (USD MILLION) 135
TABLE 86 CANADA: THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SIZE, BY APPLICATION, 2013-2020 (USD MILLION) 135
TABLE 87 AGREEMENTS, COLLABORATIONS, CONTRACTS, AND PARTNERSHIPS, 2013-2016 138
TABLE 88 MARKETING AND PROMOTIONS, 2013-2016 139
TABLE 89 NEW PRODUCT LAUNCHES, 2013-2016 140
TABLE 90 EXPANSIONS, 2013-2014 141
TABLE 91 ACQUISITIONS, 2013-2016 142
TABLE 92 OTHER STRATEGIES, 2013-2016 143


LIST OF FIGURES

FIGURE 1 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION 20
FIGURE 2 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: RESEARCH METHODOLOGY STEPS 22
FIGURE 3 KEY DATA FROM SECONDARY SOURCES 23
FIGURE 4 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND COUNTRY 25
FIGURE 5 MARKET SIZE ESTIMATION METHODOLOGY: BOTTOM-UP APPROACH 27
FIGURE 6 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 28
FIGURE 7 RESEARCH DESIGN 29
FIGURE 8 DATA TRIANGULATION METHODOLOGY 30
FIGURE 9 THERAPEUTICS MARKET TO WITNESS THE HIGHEST GROWTH RATE FROM 2015 TO 2020 31
FIGURE 10 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS THERAPEUTICS MARKET SHARE, BY TYPE, 2015 VS. 2020 32
FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, 2015 33
FIGURE 12 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS SPECT APPLICATIONS MARKET SIZE, 2015 VS. 2020 (USD MILLION) 34
FIGURE 13 ADVANCES IN RADIOTRACERS TO PROPEL MARKET GROWTH 35
FIGURE 14 THYROID APPLICATION SEGMENT DOMINATES THE NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE MARKET IN 2015 36
FIGURE 15 U.S. TO WITNESS THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD 37
FIGURE 16 DIAGNOSTICS SEGMENT TO COMMAND THE LARGEST MARKET SHARE DURING THE FORECAST PERIOD 38
FIGURE 17 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION 40
FIGURE 18 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, and CHALLENGES 41
FIGURE 19 CLINICAL TRIALS FOR DIAGNOSTIC and THERAPEUTIC RADIOISOTOPES, BY PHASE 50
FIGURE 20 CLINICAL TRIALS FOR DIAGNOSTIC and THERAPEUTIC RADIOISOTOPES, BY COMPANY and INSTITUTE 51
FIGURE 21 CLINICAL TRIALS FOR RADIOISOTOPES, BY TYPE 52
FIGURE 22 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY SUBTYPE 53
FIGURE 23 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY INDICATION 54
FIGURE 24 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY PHASE 55
FIGURE 25 CLINICAL TRIALS FOR DIAGNOSTIC RADIOISOTOPES, BY COMPANY and INSTITUTE 55
FIGURE 26 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY SUBTYPE 57
FIGURE 27 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY INDICATION 58
FIGURE 28 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY PHASE 59
FIGURE 29 CLINICAL TRIALS FOR THERAPEUTIC RADIOISOTOPES, BY COMPANY and INSTITUTE 59
FIGURE 30 NORTH AMERICAN NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET SEGMENTATION, BY TYPE 62
FIGURE 31 THERAPEUTIC SEGMENT TO GROW AT THE HIGHEST CAGR OF 10.0% 63
FIGURE 32 PET SEGMENT TO GROW AT THE HIGHEST CAGR OF 11.3% DURING THE FORECAST PERIOD 65
FIGURE 33 ALPHA EMITTERS SEGMENT TO GROW AT THE HIGHEST CAGR OF 16.8% DURING THE FORECAST PERIOD 77
FIGURE 34 NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS APPLICATIONS MARKET SEGMENTATION 90
FIGURE 35 SEGMENTATION OF NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS APPLICATIONS MARKET FOR SPECT ISOTOPES 91
FIGURE 36 U.S. TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 92
FIGURE 37 NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 7.8% DURING THE FORECAST PERIOD 93
FIGURE 38 SEGMENTATION OF NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS APPLICATIONS MARKET FOR PET ISOTOPES 99
FIGURE 39 U.S. TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 100
FIGURE 40 NEUROLOGY APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 12.6% DURING THE FORECAST PERIOD 101
FIGURE 41 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS APPLICATIONS MARKET SEGMENTATION 105
FIGURE 42 U.S. TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD 106
FIGURE 43 ENDOCRINE TUMORS APPLICATION SEGMENT TO GROW AT THE HIGHEST CAGR OF 10.8% DURING THE FORECAST PERIOD 107
FIGURE 44 U.S. TO COMMAND THE LARGEST SHARE OF THE NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET IN 2015 120
FIGURE 45 NORTH AMERICAN DIAGNOSTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET OVERVIEW 121
FIGURE 46 U.S. TO COMMAND THE LARGEST SHARE OF THE NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET IN 2015 128
FIGURE 47 NORTH AMERICAN THERAPEUTIC NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET OVERVIEW 129
FIGURE 48 TOP 5 STRATEGIES ADOPTED BY PLAYERS OVER THE LAST THREE YEARS (2013-2016) 136
FIGURE 49 BATTLE FOR MARKET SHARE: AGREEMENTS, COLLABORATIONS, CONTRACTS, AND PARTNERSHIPS WAS THE KEY STRATEGY (2013 -2016) 137
FIGURE 50 ORGANIC and INORGANIC GROWTH STRATEGIES: INDUSTRY TREND VS. KEY PLAYERS 144
FIGURE 51 ORGANIC GROWTH STRATEGIES, BY KEY PLAYER (2013-2016) 145
FIGURE 52 INORGANIC GROWTH STRATEGIES, BY KEY PLAYER (2013-2016) 146
FIGURE 53 PRODUCT MIX OF THE KEY PLAYERS IN THE MARKET 147
FIGURE 54 CARDINAL HEALTH, INC.: COMPANY SNAPSHOT 148
FIGURE 55 MALLINCKRODT PLC: COMPANY SNAPSHOT 151
FIGURE 56 GE HEALTHCARE: COMPANY SNAPSHOT 153
FIGURE 57 LANTHEUS MEDICAL IMAGING, INC.: COMPANY SNAPSHOT 155
FIGURE 58 BAYER HEALTHCARE: COMPANY SNAPSHOT 157
FIGURE 59 NORDION, INC.: COMPANY SNAPSHOT 163
FIGURE 60 ADVANCED ACCELERATOR APPLICATIONS S.A.: COMPANY SNAPSHOT 165

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

Nuclear Medicine/Radiopharmaceuticals Market by Type (Diagnostic (SPECT - Technetium, PET - F-18), Therapeutic (Beta Emitters - I-131, Alpha Emitters, Brachytherapy - Y-90) & by Application (Oncology, Thyroid, Cardiology) - Global Forecasts to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The nuclear medicine/radiopharmaceuticals market is projected to reach USD 7.27 billion by 2021 from USD 4.67 billion in 2016, growing at a CAGR of 9.3% in the next five years (2016 to 2021). Over the ...

Global Nuclear Medicine Market

Global Nuclear Medicine Market

  • $ 4250
  • Industry report
  • December 2016
  • by Mordor Intelligence LLP

The global nuclear medicines market is expected to reach USD 17,600 million by the end of 2020, growing at a CAGR of around 12.29% from 2015 to 2020. Nuclear medicine utilizes the radioisotope for application ...

Global and Chinese European Nuclear Medicine / Radiopharmaceuticals Industry, 2016 Market Research Report

Global and Chinese European Nuclear Medicine / Radiopharmaceuticals Industry, 2016 Market Research Report

  • $ 3000
  • Industry report
  • November 2016
  • by Prof Research

The ’Global and Chinese European Nuclear Medicine / Radiopharmaceuticals Industry, 2011-2021 Market Research Report’ is a professional and in-depth study on the current state of the global European ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.